Literature DB >> 16113796

Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients.

Andreas Greinacher1, Beate Farner, Hartmut Kroll, Thomas Kohlmann, Theodore E Warkentin, Petra Eichler.   

Abstract

Immune mediated heparin induced thrombocytopenia (HIT) is a prothrombotic adverse effect of heparin. However, only a subgroup of patients with HIT develops thromboembolic complications. We aimed to identify risk factors for developing HITassociated thrombosis. We analyzed a registry of patients with clinical suspicion of HIT who tested positive using a sensitive functional assay. Patient information was obtained by a standardized questionnaire. By multivariate analysis the association of age, gender, type of patient population, and magnitude of the platelet count decline with the frequency, type (venous or arterial), and temporal pattern of thrombotic events was assessed. In 408 HIT patients we observed predominance of venous thrombosis (2.4:1), with 40% of patients developing a pulmonary embolism. However, in the subgroup of post-cardiovascular surgery patients there was predominance of arterial thrombosis (1:8.5). The type of arterial thrombosis (limb artery thrombosis > thrombotic stroke > myocardial infarction) was the converse of that observed with typical atherothrombotic clots in non-HIT populations. In 59.8% of patients HIT-related thrombosis manifested either on the same day a platelet count decrease >50% was documented (26.3%) or before the decrease in platelet counts (33.5%). The most important risk factors for thrombosis were orthopedic/trauma surgery and the magnitude of platelet count decrease. HIT-associated thrombosis occurs in a considerable proportion of patients before platelet counts decrease by more than 50%.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16113796     DOI: 10.1160/TH04-12-0825

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  72 in total

1.  The Clinical Utility of the Heparin Neutralization Assay in the Diagnosis of Heparin-Induced Thrombocytopenia.

Authors:  Gang Zheng; Michael B Streiff; Clifford M Takemoto; Jennifer Bynum; Elise Gelwan; Jayesh Jani; Danielle Judge; Thomas S Kickler
Journal:  Clin Appl Thromb Hemost       Date:  2017-08-04       Impact factor: 2.389

2.  Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia.

Authors:  Lubica Rauova; Jessica D Hirsch; Teshell K Greene; Li Zhai; Vincent M Hayes; M Anna Kowalska; Douglas B Cines; Mortimer Poncz
Journal:  Blood       Date:  2010-08-19       Impact factor: 22.113

3.  Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; David F Kong; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

4.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

5.  Acute respiratory distress and hemorrhagic shock in a patient 12 days after elective hepatic surgery.

Authors:  Nektaria Xirouchaki; Eleni Mavrogeni; Eumorfia Kondili; Dimitris Georgopoulos
Journal:  Intensive Care Med       Date:  2006-12-13       Impact factor: 17.440

Review 6.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 7.  Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients.

Authors:  Daniela R Junqueira; Liliane M Zorzela; Edson Perini
Journal:  Cochrane Database Syst Rev       Date:  2017-04-21

8.  Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4.

Authors:  Rustem I Litvinov; Serge V Yarovoi; Lubica Rauova; Valeri Barsegov; Bruce S Sachais; Ann H Rux; Jillian L Hinds; Gowthami M Arepally; Douglas B Cines; John W Weisel
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

9.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

10.  Characterization of hospitalized cardiovascular patients with suspected heparin-induced thrombocytopenia.

Authors:  Felicitas Stoll; Miriel Gödde; Albrecht Leo; Hugo A Katus; Oliver J Müller
Journal:  Clin Cardiol       Date:  2018-12-03       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.